Advertisement
Screener

INSMED INC (INSM) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

3.2 / 5 stars · 43/67 Roast Me

INSMED INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-12-31 was 66.62K shares, a 58.10% increase year-over-year.
  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-09-30 was 46.36K shares, a 32.61% decline year-over-year.
  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-06-30 was 368.74K shares, a 84.93% increase year-over-year.
  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-03-31 was 12.63K shares, a 81.41% decline year-over-year.
  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 5.60M shares, a 16.29% increase from fiscal 2024.
  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 4.81M shares, a 452.03% increase from fiscal 2023.
  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 871.93K shares, a 24.27% decline from fiscal 2022.
  • INSMED INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.15M shares, a 6.79% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month
2025-12-315.60M shares
10-K · filed 2026-02-19
2024-12-314.81M shares
10-K · filed 2025-02-20
2023-12-31871.93K shares
10-K · filed 2025-02-20
2022-12-311.15M shares
10-K · filed 2025-02-20
2021-12-311.24M shares
10-K · filed 2024-02-22
2020-12-311.68M shares
10-K · filed 2023-02-23
2019-12-311.41M shares
10-K · filed 2022-02-17
2018-12-3166.62K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
494.35K shares
10-K · filed 2021-02-25
2018-09-3046.36K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30
469.87K shares
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30368.74K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
492.31K shares
derived: sum of 4 quarters · filed 2020-02-25
2018-03-3112.63K shares
10-Q · filed 2018-05-02
322.96K shares
derived: sum of 4 quarters · filed 2020-02-25
2017-12-3142.14K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
378.27K shares
10-K · filed 2020-02-25
2017-09-3068.80K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
478.12K shares
derived: sum of 4 quarters · filed 2019-02-22
2017-06-30199.39K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
409.32K shares
derived: sum of 4 quarters · filed 2019-02-22
2017-03-3167.94K shares
10-Q · filed 2017-05-03
214.97K shares
derived: sum of 4 quarters · filed 2019-02-22
2016-12-31141.98K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
162.34K shares
10-K · filed 2019-02-22
2016-09-300.00 shares
10-Q · filed 2016-11-03
30.36K shares
derived: sum of 4 quarters · filed 2018-02-23
2016-06-305.04K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
90.22K shares
derived: sum of 4 quarters · filed 2018-02-23
2016-03-3115.31K shares
10-Q · filed 2016-05-05
318.38K shares
derived: sum of 4 quarters · filed 2018-02-23
2015-12-3110.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
481.14K shares
10-K · filed 2018-02-23
2015-09-3059.86K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06
600.25K shares
derived: sum of 4 quarters · filed 2017-02-23
2015-06-30233.21K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
634.55K shares
derived: sum of 4 quarters · filed 2017-02-23
2015-03-31178.07K shares
10-Q · filed 2015-05-07
408.73K shares
derived: sum of 4 quarters · filed 2017-02-23
2014-12-31129.11K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23
283.06K shares
10-K · filed 2017-02-23
2014-09-3094.16K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
181.77K shares
derived: sum of 4 quarters · filed 2016-02-25
2014-06-307.39K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06
284.00K shares
derived: sum of 4 quarters · filed 2016-02-25
2014-03-3152.40K shares
10-Q · filed 2014-05-08
406.97K shares
derived: sum of 4 quarters · filed 2016-02-25
2013-12-3127.82K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
371.74K shares
10-K · filed 2016-02-25
2013-09-30196.38K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05
374.17K shares
derived: sum of 4 quarters · filed 2015-02-27
2013-06-30130.36K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
177.78K shares
derived: sum of 4 quarters · filed 2015-02-27
2013-03-3117.17K shares
10-Q · filed 2013-05-07
2012-12-3130.25K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
30.25K shares
10-K · filed 2015-02-27
2012-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
2011-12-315.20K shares
10-K · filed 2014-03-06
2010-12-310.00 shares
10-K · filed 2013-03-18
2009-12-3153.37K shares
10-K · filed 2012-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10